Beijing Baylx Biotechnology Co., Ltd.

Based in Beijing, China, and established in 2015, Beijing Baylx Biotechnology Co. , Ltd. is a biotechnology manufacturer that focuses on the development of stem cell therapeutics for different diseases. The company participated in the formulation of quality management standards for stem cell preparations, and its products have received the Quality Management Certificate of Stem Cell Preparation.

The company has multiple honors, including specialized, special, and new enterprises in Beijing, Zhongguancun Biomedical TOP10. Moreover, the company has obtained 2 clinical trial licenses issued by the State Drug Administration of China and 2 clinical trial licenses issued by the US Food and Drug Administration (FDA), and registered clinical trials are in progress. The company has two categories of stem cell therapeutic candidates product, Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) for autoimmune diseases and engineered hUC-MSC for malignant diseases. The autoimmune diseases include Arthritis (RA), Crohn's disease (CD), liver disease, as well as advanced cancers.

The hUC-MSC is from the human cord tissues. The advantages of hUC-MSC include the non-invasive procedure for the donor, proliferation, ex vivo scalability, and biological activities, which are better than MSC derived from other adult tissues. The company will use the Series B funding to promote the R&D progress of stem cell drugs and establish a standard factory.